CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses

Cancer Immunology, Immunotherapy

Volumn 62, Issue 4, 2013, Pages 747-760

  Corgnac, Stéphanie ^a   Perret, Rachel ^a   Derré, Laurent ^b   Zhang, Lianjun ^a   Stirnemann, Kathrin ^c   Zauderer, Maurice ^d   Speiser, Daniel E ^a   Mach, Jean Pierre ^a   Romero, Pedro ^a   Donda, Alena ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d VACCINEX INC   (United States)

Author keywords

Cancer immunotherapy; CD1d; Fusion protein; iNKT cells; Tumor targeting

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CARCINOEMBRYONIC ANTIBODY; CD1D ANTIGEN; HYBRID PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER THERAPY; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; INVARIANT NATURAL KILLER T CELL; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; ANTIGENS, CD1D; CELL LINE, TUMOR; FEMALE; GALACTOSYLCERAMIDES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; RECOMBINANT FUSION PROTEINS;

EID: 84877812574     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1381-7     Document Type: Article

References (42)

1. Van Kaer L (2007) NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 19(3):354-364. doi: 10.1016/j.coi.2007.03.001
2. Cerundolo V, Silk JD, Masri SH, Salio M (2009) Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 9(1):28-38. doi: 10.1038/nri2451
3. Berzins SP, Smyth MJ, Baxter AG (2011) Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 11(2):131-142. doi: 10.1038/nri2904
4. Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3(9):867-874
5. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI (2002) Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99(4):1259-1266
6. Takeda K, Hayakawa Y, Atsuta M, Hong S, Van Kaer L, Kobayashi K, Ito M, Yagita H, Okumura K (2000) Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 12(6):909-914
7. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA (2001) Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167(7):4046-4050
8. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K (2002) Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol 168(12):6494-6499
9. Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S, Groshen S, Wilson SB, Seeger RC (2004) Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 199(9):1213-1221. doi: 10.1084/jem.20031462
10. Schneiders FL, de Bruin RC, van den Eertwegh AJ, Scheper RJ, Leemans CR, Brakenhoff RH, Langendijk JA, Verheul HM, de Gruijl TD, Molling JW, van der Vliet HJ (2012) Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up. Am J Clin Oncol 30(5):567-570. doi: 10.1200/JCO.2011.38.8819
11. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ (2004) Therapeutic activation of Valpha24+ Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103(2):383-389
12. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8(12):3702-3709
13. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11(5):1910-1917
14. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar MV (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201(9):1503-1517
15. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, Sakurai D, Taniguchi M, Nakayama T, Okamoto Y (2009) Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 100(6):1092-1098. doi: 10.1111/j.1349-7006.2009.01135.x
16. Nicol AJ, Tazbirkova A, Nieda M (2011) Comparison of clinical and immunological effects of intravenous and intradermal administration of {alpha}-galactosylCeramide (KRN7000) - pulsed dendritic cells. Clin Cancer Res 17(15):5140-5151. doi: 10.1158/1078-0432.CCR-10-3105
17. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278(5343):1626-1629
18. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115(9):2572-2583
19. Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Wurm F, Corradin G, Mach JP, Macdonald HR, Donda A (2008) Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J Clin Invest 118(3):994-1005. doi: 10.1172/JCI33249
20. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ (1998) Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 58(7):1469-1477
21. Shao Q, Ning H, Lv J, Liu Y, Zhao X, Ren G, Feng A, Xie Q, Sun J, Song B, Yang Y, Gao W, Ding K, Yang M, Hou M, Peng J, Qu X (2012) Regulation of Th1/Th2 polarization by tissue inhibitor of metalloproteinase-3 via modulating dendritic cells. Blood 119(20):4636-4644. doi: 10.1182/blood-2011-08-376418
22. Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N, Cerottini JC, Romero P, Porcelli SA, Macdonald HR, Speiser DE (2009) Enrichment of human CD4 + V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J immunol 182(8):5140-5151. doi: 10.4049/jimmunol.0711086
23. Hardman N, Gill LL, De Winter RF, Wagner K, Hollis M, Businger F, Ammaturo D, Buchegger F, Mach JP, Heusser C (1989) Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen. Int J Cancer 44(3):424-433
24. Verhaar MJ, Chester KA, Keep PA, Robson L, Pedley RB, Boden JA, Hawkins RE, Begent RH (1995) A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer 61(4):497-501
25. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I, Okumura K (2001) Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 31(6):1720-1727
26. Metelitsa LS (2011) Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin immunol 140(2):119-129. doi: 10.1016/j.clim.2010.10.005
27. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR (2008) Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 111(12):5637-5645. doi: 10.1182/blood-2007-05-092866
28. Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M, Yagita H, Kang CY (2008) Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 181(10):6707-6710
29. Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, Kumar V, Wu L, Kaer LV (2009) PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 182(5):2816-2826. doi: 10.4049/jimmunol.0803648
30. Iyoda T, Ushida M, Kimura Y, Minamino K, Hayuka A, Yokohata S, Ehara H, Inaba K (2010) Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. Int Immunol 22(11):905-913. doi: 10.1093/intimm/dxq444
31. Wang J, Cheng L, Wondimu Z, Swain M, Santamaria P, Yang Y (2009) Cutting edge: cD28 engagement releases antigen-activated invariant NKT cells from the inhibitory effects of PD-1. J immunol 182(11):6644-6647. doi: 10.4049/jimmunol.0804050
32. Miller ML, Sun Y, Fu YX (2009) Cutting edge: B and T lymphocyte attenuator signaling on NKT cells inhibits cytokine release and tissue injury in early immune responses. J immunol 183(1):32-36. doi: 10.4049/jimmunol.0900690
33. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y (2008) Phase I study of alpha- galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 57(3):337-345. doi: 10.1007/s00262-007-0373-5
34. Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305-334. doi: 10.1146/annurev.immunol.21.120601.141110
35. Cochran JR, Cameron TO, Stern LJ (2000) The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity 12(3):241-250
36. Stone JD, Stern LJ (2006) CD8 T cells, like CD4 T cells, are triggered by multivalent engagement of TCRs by MHC-peptide ligands but not by monovalent engagement. J immunol 176(3):1498-1505
37. Bagnara D, Ibatici A, Corselli M, Sessarego N, Tenca C, De Santanna A, Mazzarello A, Daga A, Corvo R, De Rossi G, Frassoni F, Ciccone E, Fais F (2009) Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms. Haematologica 94(7):967-974. doi: 10.3324/haematol.2008.001339
38. Dhodapkar MV, Richter J (2011) Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol 140(2):160-166. doi: 10.1016/j.clim.2010.12.010
39. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S (2007) Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 204(11):2641-2653. doi: 10.1084/jem.20070458
40. Wingender G, Krebs P, Beutler B, Kronenberg M (2010) Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. J immunol 185(5):2721-2729. doi: 10.4049/jimmunol.1001018
41. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, Okamoto Y (2011) Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 138(3):255-265. doi: 10.1016/j.clim.2010.11.014
42. Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, von Blomberg BM, Scheper RJ, van den Eertwegh AJ (2007) Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25(7):862-868. doi: 10.1200/JCO.2006.08.5787